-
1
-
-
84904155440
-
Cancer treatment and survivorship statistics, 2014
-
De Santis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64:252-271.
-
(2014)
CA Cancer J Clin.
, vol.64
, pp. 252-271
-
-
De Santis, C.E.1
Lin, C.C.2
Mariotto, A.B.3
Siegel, R.L.4
Stein, K.D.5
Kramer, J.L.6
Alteri, R.7
Robbins, A.S.8
Jemal, A.9
-
2
-
-
0030200669
-
Central nervous system metastasis in breast cancer
-
Boogerd W. Central nervous system metastasis in breast cancer. Radiother Oncol. 1996; 40:5-22.
-
(1996)
Radiother Oncol.
, vol.40
, pp. 5-22
-
-
Boogerd, W.1
-
3
-
-
84906066755
-
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
-
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014; 147:103-112.
-
(2014)
Breast Cancer Res Treat.
, vol.147
, pp. 103-112
-
-
Niikura, N.1
Hayashi, N.2
Masuda, N.3
Takashima, S.4
Nakamura, R.5
Watanabe, K.6
Kanbayashi, C.7
Ishida, M.8
Hozumi, Y.9
Tsuneizumi, M.10
Kondo, N.11
Naito, Y.12
Honda, Y.13
-
4
-
-
84893562519
-
Chimeric antigen receptor therapy for cancer
-
Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014; 65:333-347.
-
(2014)
Annu Rev Med.
, vol.65
, pp. 333-347
-
-
Barrett, D.M.1
Singh, N.2
Porter, D.L.3
Grupp, S.A.4
June, C.H.5
-
5
-
-
0037103311
-
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
-
Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002; 100:1265-1273.
-
(2002)
Blood.
, vol.100
, pp. 1265-1273
-
-
Uherek, C.1
Tonn, T.2
Uherek, B.3
Becker, S.4
Schnierle, B.5
Klingemann, H.G.6
Wels, W.7
-
6
-
-
84887327848
-
Expression of selected proteins in breast cancer brain metastases
-
Gojis O, Kubecova M, Rosina J, Vranova J, Celko M, Frajerova D, Zmrhal J, Zahumensky J, Bacova T, Baca V, Mandys V, Kucera E. Expression of selected proteins in breast cancer brain metastases. Folia Histochem Cytobiol. 2013; 51:213-218.
-
(2013)
Folia Histochem Cytobiol.
, vol.51
, pp. 213-218
-
-
Gojis, O.1
Kubecova, M.2
Rosina, J.3
Vranova, J.4
Celko, M.5
Frajerova, D.6
Zmrhal, J.7
Zahumensky, J.8
Bacova, T.9
Baca, V.10
Mandys, V.11
Kucera, E.12
-
7
-
-
84887019788
-
Nuclear EGFR as a molecular target in cancer
-
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013; 108:370-377.
-
(2013)
Radiother Oncol.
, vol.108
, pp. 370-377
-
-
Brand, T.M.1
Iida, M.2
Luthar, N.3
Starr, M.M.4
Huppert, E.J.5
Wheeler, D.L.6
-
9
-
-
33749843288
-
Herpes simplex virus 1 (HSV-1) for cancer treatment
-
Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006; 13:975-992.
-
(2006)
Cancer Gene Ther.
, vol.13
, pp. 975-992
-
-
Shen, Y.1
Nemunaitis, J.2
-
10
-
-
84884594361
-
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma
-
Robert HI. Andtbacka FAC, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013; 31.
-
(2013)
J Clin Oncol
, pp. 31
-
-
Robert, H.I.1
Andtbacka, F.A.C.2
Amatruda, T.3
Senzer, N.N.4
Chesney, J.5
Delman, K.A.6
-
11
-
-
84870909657
-
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
-
Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012; 18:1827-1834.
-
(2012)
Nat Med.
, vol.18
, pp. 1827-1834
-
-
Alvarez-Breckenridge, C.A.1
Yu, J.2
Price, R.3
Wojton, J.4
Pradarelli, J.5
Mao, H.6
Wei, M.7
Wang, Y.8
He, S.9
Hardcastle, J.10
Fernandez, S.A.11
Kaur, B.12
Lawler, S.E.13
-
12
-
-
84955485418
-
TGFbeta Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
-
Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, et al. TGFbeta Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 2015; 75:5273-5282.
-
(2015)
Cancer Res.
, vol.75
, pp. 5273-5282
-
-
Han, J.1
Chen, X.2
Chu, J.3
Xu, B.4
Meisen, W.H.5
Chen, L.6
Zhang, L.7
Zhang, J.8
He, X.9
Wang, Q.E.10
Chiocca, E.A.11
Kaur, B.12
Caligiuri, M.A.13
-
13
-
-
84908073316
-
Chimeric antigen receptor T cells for sustained remissions in leukemia
-
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371:1507-1517.
-
(2014)
N Engl J Med.
, vol.371
, pp. 1507-1517
-
-
Maude, S.L.1
Frey, N.2
Shaw, P.A.3
Aplenc, R.4
Barrett, D.M.5
Bunin, N.J.6
Chew, A.7
Gonzalez, V.E.8
Zheng, Z.9
Lacey, S.F.10
Mahnke, Y.D.11
Melenhorst, J.J.12
Rheingold, S.R.13
-
14
-
-
84861406715
-
The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon
-
Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol. 2012; 86:4566-4577.
-
(2012)
J Virol.
, vol.86
, pp. 4566-4577
-
-
Alvarez-Breckenridge, C.A.1
Yu, J.2
Price, R.3
Wei, M.4
Wang, Y.5
Nowicki, M.O.6
Ha, Y.P.7
Bergin, S.8
Hwang, C.9
Fernandez, S.A.10
Kaur, B.11
Caligiuri, M.A.12
Chiocca, E.A.13
-
15
-
-
84942850084
-
The Impact of Macrophageand Microglia-Secreted TNFalpha on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
-
Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B. The Impact of Macrophageand Microglia-Secreted TNFalpha on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res. 2015.
-
(2015)
Clin Cancer Res.
-
-
Meisen, W.H.1
Wohleb, E.S.2
Jaime-Ramirez, A.C.3
Bolyard, C.4
Yoo, J.Y.5
Russell, L.6
Hardcastle, J.7
Dubin, S.8
Muili, K.9
Yu, J.10
Caligiuri, M.11
Godbout, J.12
Kaur, B.13
-
16
-
-
84923019006
-
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
-
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385:517-528.
-
(2015)
Lancet.
, vol.385
, pp. 517-528
-
-
Lee, D.W.1
Kochenderfer, J.N.2
Stetler-Stevenson, M.3
Cui, Y.K.4
Delbrook, C.5
Feldman, S.A.6
Fry, T.J.7
Orentas, R.8
Sabatino, M.9
Shah, N.N.10
Steinberg, S.M.11
Stroncek, D.12
Tschernia, N.13
-
17
-
-
84894443958
-
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
-
Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kuhlcke K, Westwood N, Thistlethwaite F, Hawkins RE, et al. Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother. 2014; 63:133-145.
-
(2014)
Cancer Immunol Immunother.
, vol.63
, pp. 133-145
-
-
Guest, R.D.1
Kirillova, N.2
Mowbray, S.3
Gornall, H.4
Rothwell, D.G.5
Cheadle, E.J.6
Austin, E.7
Smith, K.8
Watt, S.M.9
Kuhlcke, K.10
Westwood, N.11
Thistlethwaite, F.12
Hawkins, R.E.13
-
18
-
-
84942910678
-
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
-
Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res. 2015.
-
(2015)
Clin Cancer Res
-
-
Katz, S.C.1
Burga, R.A.2
McCormack, E.3
Wang, L.J.4
Mooring, W.5
Point, G.R.6
Khare, P.D.7
Thorn, M.8
Ma, Q.9
Stainken, B.F.10
Assanah, E.O.11
Davies, R.12
Espat, N.J.13
-
19
-
-
0025864440
-
Experimental therapy of human glioma by means of a genetically engineered virus mutant
-
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252:854-856.
-
(1991)
Science.
, vol.252
, pp. 854-856
-
-
Martuza, R.L.1
Malick, A.2
Markert, J.M.3
Ruffner, K.L.4
Coen, D.M.5
-
20
-
-
0035499267
-
Stem cells, cancer, and cancer stem cells
-
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414:105-111.
-
(2001)
Nature.
, vol.414
, pp. 105-111
-
-
Reya, T.1
Morrison, S.J.2
Clarke, M.F.3
Weissman, I.L.4
-
21
-
-
84937010762
-
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
-
Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. 2015; 5:11483. doi: 10.1038/srep11483.
-
(2015)
Sci Rep.
, vol.5
, pp. 11483
-
-
Han, J.1
Chu, J.2
Keung Chan, W.3
Zhang, J.4
Wang, Y.5
Cohen, J.B.6
Victor, A.7
Meisen, W.H.8
Kim, S.H.9
Grandi, P.10
Wang, Q.E.11
He, X.12
Nakano, I.13
-
22
-
-
84866383076
-
Treatment of breast cancer stem cells with oncolytic herpes simplex virus
-
Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, Liu R. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012; 19:707-714.
-
(2012)
Cancer Gene Ther.
, vol.19
, pp. 707-714
-
-
Li, J.1
Zeng, W.2
Huang, Y.3
Zhang, Q.4
Hu, P.5
Rabkin, S.D.6
Liu, R.7
-
23
-
-
16844373011
-
Optimizing the treatment of metastatic breast cancer
-
Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005; 89:S9-S15.
-
(2005)
Breast Cancer Res Treat.
, vol.89
, pp. S9-S15
-
-
Gralow, J.R.1
-
25
-
-
0037388204
-
Prospective identification of tumorigenic breast cancer cells
-
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100:3983-3988.
-
(2003)
Proc Natl Acad Sci U S A.
, vol.100
, pp. 3983-3988
-
-
Al-Hajj, M.1
Wicha, M.S.2
Benito-Hernandez, A.3
Morrison, S.J.4
Clarke, M.F.5
-
26
-
-
84923912770
-
Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
-
Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015; 16:1.
-
(2015)
BMC Immunol.
, vol.16
, pp. 1
-
-
Deng, Z.1
Wu, Y.2
Ma, W.3
Zhang, S.4
Zhang, Y.Q.5
-
27
-
-
84905445848
-
Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells
-
Lee CH, Wu YT, Hsieh HC, Yu Y, Yu AL, Chang WW. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells. Biochimie. 2014; 104:117-126.
-
(2014)
Biochimie.
, vol.104
, pp. 117-126
-
-
Lee, C.H.1
Wu, Y.T.2
Hsieh, H.C.3
Yu, Y.4
Yu, A.L.5
Chang, W.W.6
-
28
-
-
84865636298
-
Highly sensitive profiling of CD44+/CD24-breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway
-
Hardt O, Wild S, Oerlecke I, Hofmann K, Luo S, Wiencek Y, Kantelhardt E, Vess C, Smith GP, Schroth GP, Bosio A, Dittmer J. Highly sensitive profiling of CD44+/CD24-breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway. Cancer Lett. 2012; 325:165-174.
-
(2012)
Cancer Lett.
, vol.325
, pp. 165-174
-
-
Hardt, O.1
Wild, S.2
Oerlecke, I.3
Hofmann, K.4
Luo, S.5
Wiencek, Y.6
Kantelhardt, E.7
Vess, C.8
Smith, G.P.9
Schroth, G.P.10
Bosio, A.11
Dittmer, J.12
-
29
-
-
78449294111
-
EGFR signaling in breast cancer: bad to the bone
-
Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ 2nd. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol. 2010; 21:951-960.
-
(2010)
Semin Cell Dev Biol.
, vol.21
, pp. 951-960
-
-
Foley, J.1
Nickerson, N.K.2
Nam, S.3
Allen, K.T.4
Gilmore, J.L.5
Nephew, K.P.6
Riese, D.J.7
-
31
-
-
35248889408
-
EGFR associated expression profiles vary with breast tumor subtype
-
Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007; 8:258.
-
(2007)
BMC Genomics.
, vol.8
, pp. 258
-
-
Hoadley, K.A.1
Weigman, V.J.2
Fan, C.3
Sawyer, L.R.4
He, X.5
Troester, M.A.6
Sartor, C.I.7
Rieger-House, T.8
Bernard, P.S.9
Carey, L.A.10
Perou, C.M.11
-
32
-
-
84885356671
-
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma
-
Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013; 24:438-449.
-
(2013)
Cancer Cell.
, vol.24
, pp. 438-449
-
-
Fan, Q.W.1
Cheng, C.K.2
Gustafson, W.C.3
Charron, E.4
Zipper, P.5
Wong, R.A.6
Chen, J.7
Lau, J.8
Knobbe-Thomsen, C.9
Weller, M.10
Jura, N.11
Reifenberger, G.12
Shokat, K.M.13
-
33
-
-
1842413083
-
Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas
-
Maenpaa A, Kovanen PE, Paetau A, Jaaskelainen J, Timonen T. Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas. Acta Neuropathol. 1997; 94:216-225.
-
(1997)
Acta Neuropathol.
, vol.94
, pp. 216-225
-
-
Maenpaa, A.1
Kovanen, P.E.2
Paetau, A.3
Jaaskelainen, J.4
Timonen, T.5
-
34
-
-
4544258999
-
EGFR and EGFRvIII expression in primary breast cancer and cell lines
-
Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat. 2004; 87:87-95.
-
(2004)
Breast Cancer Res Treat.
, vol.87
, pp. 87-95
-
-
Rae, J.M.1
Scheys, J.O.2
Clark, K.M.3
Chadwick, R.B.4
Kiefer, M.C.5
Lippman, M.E.6
-
35
-
-
84905511196
-
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells
-
Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine SM, He X, Bai XF, Hofmeister CC, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014; 20:3989-4000.
-
(2014)
Clin Cancer Res.
, vol.20
, pp. 3989-4000
-
-
Chu, J.1
He, S.2
Deng, Y.3
Zhang, J.4
Peng, Y.5
Hughes, T.6
Yi, L.7
Kwon, C.H.8
Wang, Q.E.9
Devine, S.M.10
He, X.11
Bai, X.F.12
Hofmeister, C.C.13
-
36
-
-
65449177238
-
NK cells recognize and kill human glioblastoma cells with stem cell-like properties
-
Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009; 182:3530-3539.
-
(2009)
J Immunol.
, vol.182
, pp. 3530-3539
-
-
Castriconi, R.1
Daga, A.2
Dondero, A.3
Zona, G.4
Poliani, P.L.5
Melotti, A.6
Griffero, F.7
Marubbi, D.8
Spaziante, R.9
Bellora, F.10
Moretta, L.11
Moretta, A.12
Corte, G.13
-
38
-
-
16844366956
-
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor
-
Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005; 65:2832-2839.
-
(2005)
Cancer Res.
, vol.65
, pp. 2832-2839
-
-
Kambara, H.1
Okano, H.2
Chiocca, E.A.3
Saeki, Y.4
-
39
-
-
80052666221
-
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
-
Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011; 13:R87.
-
(2011)
Breast Cancer Res.
, vol.13
, pp. R87
-
-
Sihto, H.1
Lundin, J.2
Lundin, M.3
Lehtimaki, T.4
Ristimaki, A.5
Holli, K.6
Sailas, L.7
Kataja, V.8
Turpeenniemi-Hujanen, T.9
Isola, J.10
Heikkila, P.11
Joensuu, H.12
-
40
-
-
84921507719
-
Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies
-
Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B. Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther. 2015; 14:307-314.
-
(2015)
Mol Cancer Ther.
, vol.14
, pp. 307-314
-
-
Meisen, W.H.1
Dubin, S.2
Sizemore, S.T.3
Mathsyaraja, H.4
Thies, K.5
Lehman, N.L.6
Boyer, P.7
Jaime-Ramirez, A.C.8
Elder, J.B.9
Powell, K.10
Chakravarti, A.11
Ostrowski, M.C.12
Kaur, B.13
-
41
-
-
84904869718
-
Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors
-
Kanai R, Rabkin SD. Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol. 2013; 2:129-142.
-
(2013)
CNS Oncol.
, vol.2
, pp. 129-142
-
-
Kanai, R.1
Rabkin, S.D.2
-
42
-
-
84922257867
-
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor
-
Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Kohl U, Kloess S, Kohler S, Holtgreve-Grez H, Jauch A, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015; 23:330-338.
-
(2015)
Mol Ther.
, vol.23
, pp. 330-338
-
-
Schonfeld, K.1
Sahm, C.2
Zhang, C.3
Naundorf, S.4
Brendel, C.5
Odendahl, M.6
Nowakowska, P.7
Bonig, H.8
Kohl, U.9
Kloess, S.10
Kohler, S.11
Holtgreve-Grez, H.12
Jauch, A.13
-
43
-
-
0036405461
-
Management of brain metastases
-
Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002; 249:1357-1369.
-
(2002)
J Neurol.
, vol.249
, pp. 1357-1369
-
-
Soffietti, R.1
Ruda, R.2
Mutani, R.3
-
44
-
-
2542440873
-
A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
-
Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K, Imai K, Matsuno S, Kumagai I, et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother. 2004; 53:497-509.
-
(2004)
Cancer Immunol Immunother.
, vol.53
, pp. 497-509
-
-
Hayashi, H.1
Asano, R.2
Tsumoto, K.3
Katayose, Y.4
Suzuki, M.5
Unno, M.6
Kodama, H.7
Takemura, S.8
Yoshida, H.9
Makabe, K.10
Imai, K.11
Matsuno, S.12
Kumagai, I.13
-
45
-
-
75649122988
-
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets
-
Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood. 2010; 115:274-281.
-
(2010)
Blood.
, vol.115
, pp. 274-281
-
-
Yu, J.1
Mao, H.C.2
Wei, M.3
Hughes, T.4
Zhang, J.5
Park, I.K.6
Liu, S.7
McClory, S.8
Marcucci, G.9
Trotta, R.10
Caligiuri, M.A.11
-
46
-
-
0242719924
-
Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia
-
Hayon T, Dvilansky A, Shpilberg O, Nathan I. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma. 2003; 44:1957-1962.
-
(2003)
Leuk Lymphoma.
, vol.44
, pp. 1957-1962
-
-
Hayon, T.1
Dvilansky, A.2
Shpilberg, O.3
Nathan, I.4
-
47
-
-
77955651021
-
A simple and sensitive method for measuring tumor-specific T cell cytotoxicity
-
Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N, Zhang X. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010; 5:e11867.
-
(2010)
PLoS One.
, vol.5
-
-
Fu, X.1
Tao, L.2
Rivera, A.3
Williamson, S.4
Song, X.T.5
Ahmed, N.6
Zhang, X.7
|